Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.8895
Revised: October 28, 2013
Accepted: November 18, 2013
Published online: December 21, 2013
Core tip: Chronic hepatitis B virus (HBV) infection is the key driving force of hepatocellular carcinoma (HCC). In this review, we discussed the mechanism of HBV induction of HCC and described the current trends in anti-HBV therapy. The associations of anti-HBV therapy with prevention of HCC incidence and recurrence after curative operations were also summarized. Moreover, based on our center’s experiences, a standardized antiviral strategy was suggested which greatly benefited those patients who underwent hepatectomy and liver transplantation with regard to better clinical results.